• Home
  • Search Results
  • Germinal center B-cells resist transformation by Kras independently of tumor suppressor Arf.

Germinal center B-cells resist transformation by Kras independently of tumor suppressor Arf.

PloS one (2013-07-05)
Chelsea D Mullins, Mack Y Su, Vishwanathan Hucthagowder, Liang Chu, Lan Lu, Shashikant Kulkarni, Deborah Novack, Ravi Vij, Michael H Tomasson

Activating mutations in Ras (N- and K-) are the most common point mutations found in patients with multiple myeloma (MM) and are associated with poor clinical outcome. We sought to directly examine the role of Ras activation in MM pathogenesis and used two different tissue-specific Cre recombinase mouse lines (Cγ1-Cre and AID-Cre), to generate mice with mutant Kras (Kras(G12D) ) activated specifically in germinal center B-cells. We also generated mice with activation of the Kras(G12D) allele in a tumor-prone Arf-null genetic background. Surprisingly, we observed no significant disruption in B-cell homeostasis in any of these models by serum immunoglobulin ELISA, SPEP, flow cytometry and histological examination. We observed development of non-overlapping tumor types due to off-target Cre expression, but despite successful recombination in germinal center and later B-cell populations, we observed no B-cell phenotype. Together, these data demonstrate that Ras activation is not sufficient to transform primary germinal center B-cells, even in an Arf-null context, and that the temporal order of mutation acquisition may be critical for myeloma development. Specific pathways, yet to be identified, are required before Kras can contribute to the development of MM.

Product Number
Product Description

Extract-N-Amp Tissue PCR Kit, sufficient for 100 extractions, sufficient for 100 amplifications
Extract-N-Amp Tissue PCR Kit, sufficient for 1000 extractions, sufficient for 1000 amplifications

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.